NEWS: 公告在東京證券交易所JASDAQ標準市場新上市



Intravenous Immunoglobulin Market - Growth, Trends, and Forecasts (2020 - 2025)

出版商 Mordor Intelligence Pvt Ltd 商品編碼 921992
出版日期 內容資訊 英文 111 Pages
商品交期: 2-3個工作天內
全球靜脈注射免疫球蛋白市場:成長,趨勢,及預測 Intravenous Immunoglobulin Market - Growth, Trends, and Forecasts (2020 - 2025)
出版日期: 2020年06月01日內容資訊: 英文 111 Pages



第1章 簡介

  • 調查成果
  • 調查的前提條件
  • 調查範圍

第2章 調查方法

第3章 摘要整理

第4章 市場動態

  • 市場概況
  • 市場成長要素
    • 老年人口的增加
    • 免疫球蛋白治療的採用增加
    • 免疫不全症和出血性疾病的盛行率上升
  • 市場阻礙因素
    • 嚴格的政府法規
    • 治療費用高
  • 波特的五力分析

第5章 市場區隔

  • 各類型
    • IGG
    • IGA
    • IGM
    • IGE
    • IGD
  • 各用途
    • 低球蛋白血症
    • 慢性脫髓鞘多發性神經炎(CIDP)
    • 原發性免疫缺陷症
    • 重症肌無力
    • 多病灶性運動神經病變
    • 其他
  • 各地區
    • 北美
    • 歐洲
    • 亞太地區
    • 中東·非洲
    • 南美

第6章 競爭情形

  • 企業簡介
    • Bio Products Laboratory Ltd.
    • Biotest AG
    • China Biologic Products Holdings, Inc.
    • CSL Behring
    • Grifols, SA
    • Kedrion SpA
    • LFB SA and Shanghai RAAS Blood Products Co., Ltd.
    • Octapharma
    • 武田藥品工業株式會社

第7章 市場機會及今後趨勢


Product Code: 67646

Intravenous Immunoglobulin (IVIG) therapy is the use of a mixture of antibodies (immunoglobulins) to treat health conditions including primary immunodeficiency, immune thrombocytopenic purpura, chronic inflammatory demyelinating polyneuropathy, Kawasaki disease, certain cases of HIV/AIDS and measles, Guillain-Barre syndrome, and in certain other infections. Depending on the formulation it can be injected into muscle, a vein, or under the skin.

Increase in geriatric population, prevalence of immunodeficiency disorders and bleeding disorders have led to an increase in deamnd for novel intravenous immunoglobulin therapies. This has led to increase in the adoption rate of these therapies. Hence these factors have helped the market growth. However, stringent regulatory approval processes and regulations, and the high cost of therapy have been restraining the growth of the market.

Key Market Trends

Primary Immunodeficiency Diseases Treatment is Expected to Register a High CAGR

As per a report by Christine McCusker et al., published in Allergy, Asthma & Clinical Immunology Journal, 2018, Primary immunodeficiency diseases are more frequent than previously believed, with an estimated prevalence of 1 in 1200 live births. IgA deficiency is the most common PID, occurring in approximately 1 in 300 to 1 in 500 persons.

Intravenous immunoglobulin (IVIG) therapy has been used in primary immunodeficiency diseases (PI), other immune deficiency disorders. There are several specific medical therapies available for people with PI with antibody deficiency that account for more than half of the primary immunodeficiencies. These illnesses, such as Common Variable Immune Deficiency (CVID), X-Linked Agammaglobulinemia (XLA) and other disorders, are characterized by a lack of and/or impaired antibody function.

Hence, with availability of IVIG therapies for treating the high prevalent primary immunodeficiency diseases, the market is expected to grow in the future.

North America is Expected to Dominate the Intravenous Immunoglobulin Market

The North American countries like the United States (US) and Canada have a developed and well-structured health care system. These systems also encourage research and development. These policies encourage global players to enter the US and Canada. As a result, these countries enjoy the presence of many global market players.

Furthermore, these countries have a large portion of population that is insured. This enables this population to get medicines and therapies at subsidized rates. Hence, as increasing demand is met by the presence of global players in the region, the market is further expected to increase.

Competitive Landscape

Majority of the intravenous immunoglobulin therapies are being manufactured by the global key players. Market leaders with more funds for research and better distribution system have established their position in the market. Moreover, Asia-pacific is witnessing an emergence of some small players due to the rise of awareness. This has also helped the market grow.

Reasons to Purchase this report:

  • The market estimate (ME) sheet in Excel format
  • 3 months of analyst support

Table of Contents


  • 1.1 Study Deliverables
  • 1.2 Study Assumptions
  • 1.3 Scope of the Study




  • 4.1 Market Overview
  • 4.2 Market Drivers
    • 4.2.1 Rise in Geriatric Population
    • 4.2.2 Increase in Adoption of Immunoglobulin Treatment
    • 4.2.3 Growth in Prevalence of Immunodeficiency Diseases and Bleeding Disorders
  • 4.3 Market Restraints
    • 4.3.1 Stringent Government Regulations
    • 4.3.2 High Cost of Therapy
  • 4.4 Porter's Five Force Analysis
    • 4.4.1 Threat of New Entrants
    • 4.4.2 Bargaining Power of Buyers/Consumers
    • 4.4.3 Bargaining Power of Suppliers
    • 4.4.4 Threat of Substitute Products
    • 4.4.5 Intensity of Competitive Rivalry


  • 5.1 By Type
    • 5.1.1 IgG
    • 5.1.2 IgA
    • 5.1.3 IgM
    • 5.1.4 IgE
    • 5.1.5 IgD
  • 5.2 By Application
    • 5.2.1 Hypogammaglobulinemia
    • 5.2.2 Chronic Inflammatory Demyelinating polyneuropathy (CIDP)
    • 5.2.3 Primary Immunodeficiency Diseases
    • 5.2.4 Myasthenia Gravis
    • 5.2.5 Multifocal Motor Neuropathy
    • 5.2.6 Others
  • 5.3 Geography
    • 5.3.1 North America
      • United States
      • Canada
      • Mexico
    • 5.3.2 Europe
      • Germany
      • United Kingdom
      • France
      • Italy
      • Spain
      • Rest of Europe
    • 5.3.3 Asia-Pacific
      • China
      • Japan
      • India
      • Australia
      • South Korea
      • Rest of Asia-Pacific
    • 5.3.4 Middle-East and Africa
      • GCC
      • South Africa
      • Rest of Middle East and Africa
    • 5.3.5 South America
      • Brazil
      • Argentina
      • Rest of South America


  • 6.1 Company Profiles
    • 6.1.1 Bio Products Laboratory Ltd.
    • 6.1.2 Biotest AG
    • 6.1.3 China Biologic Products Holdings, Inc.
    • 6.1.4 CSL Behring
    • 6.1.5 Grifols, S.A.
    • 6.1.6 Kedrion S.p.A
    • 6.1.7 LFB SA and Shanghai RAAS Blood Products Co., Ltd.
    • 6.1.8 Octapharma
    • 6.1.9 Takeda Pharmaceutical Company Limited